Consider shorting Galecto (GLTO), which is viewed as a reverse merger that should trade back down to $10 or less. Another high-conviction short is Quantum (QUBT/QBTS), which is suggested as a perpetual short due to concerns about the company's legitimacy. For a long-term investment, InflaRx (IFRX) is presented as an undervalued biotech with a promising drug, but be prepared to hold it for at least a year. Biohaven (BHVN) is also a favored long position due to its strong Wall Street support and ability to raise capital. While fundamentally bullish on NVIDIA (NVDA) and Palantir (PLTR), the analyst has sold short-term positions to take profits after their significant run-ups.

Palantir (PLTR)

• The speaker is extremely bullish on Palantir, repeatedly calling its performance a "rocket ship," "breathtaking," and "insane."
• He mentions taking a "big levered long bet" on the company through call options.
• He expresses regret over not holding onto some calls that expired, which would have resulted in a 50X gain, turning a $50,000 position into $2.5 million.
• Despite his bullishness, he states, "I sold all my Palantir calls" to take profits, noting, "sometimes you gotta take the gains and move on."
• He describes Palantir as a "great company" with "very, very good" management, making it "hard to bet against."

Takeaways

• The speaker has a very positive long-term view of Palantir as a company.
• However, he has taken profits on his short-term trading positions after a significant price increase. This suggests that while he believes in the company, he felt the stock was due for a pause or that it was prudent to lock in substantial gains.
• Investors might see this as a signal that the company is fundamentally strong, but the stock's recent run-up may have made it less attractive for a new short-term trade.

NVIDIA (NVDA)

• The speaker is happy about the stock being up 3.5% and mentions he took a "big levered long bet" on it alongside Palantir.
• He states he is about to "sell all my Nvidia calls" to lock in profits from the recent rally in big tech.
• He notes the immense scale of the company, observing that the market cap of the entire pharmaceutical industry is equivalent to just one NVIDIA.

Takeaways

• Similar to his position on Palantir, the speaker is bullish on NVIDIA but is actively taking profits after a strong move up.
• His strategy appears to be capitalizing on short-term momentum in "big tech" and then exiting the position rather than holding indefinitely.
• This could be interpreted as a tactical move to secure gains, not necessarily a change in his long-term positive view of the company.

Galecto (GLTO)

• The speaker identifies GLTO as a "reverse merger."
• He has a bearish view, calling it a "good short."
• He provides a specific price target, stating it "should trade back down to $10 or less."
• A potential risk factor for short-sellers is mentioned: it is "not easy to borrow shares."

Takeaways

• The speaker believes Galecto is overvalued and presents a short-selling opportunity.
• The target is a significant drop to $10 or lower.
• Anyone considering this trade should be aware that finding shares to borrow for a short position might be difficult.

InflaRx (IFRX)

• The speaker discloses that he is long IFRX.
• He describes it as a biotech company with a drug for Hidradenitis Suppurativa (HS), which he notes is a "big market."
• He highlights positive attributes: the drug "seems to work" and is an "oral drug" (a pill), which can be an advantage.
• He believes the stock is "honestly pretty cheap."
• He includes a significant risk/caveat: "it's biotech you might have to sit on this thing for a year."

Takeaways

• IFRX is presented as a potentially undervalued biotech investment with a promising drug in a large market.
• This is not a short-term trade. Investors should be prepared for a long holding period and the inherent volatility of the biotech sector.

Quantum (Likely QUBT/QBTS)

• The speaker's sentiment is extremely bearish and sarcastic.
• He sarcastically states, "Quantum is the best. They're totally, totally not fraudulent at all," strongly implying he believes the company is fraudulent.
• He makes a direct recommendation: "I think it's always a good time to short quantum."

Takeaways

• The speaker has a deeply negative view of this company and suggests it is a perpetual short-selling candidate.
• The strong, sarcastic language implies he has zero confidence in the company's legitimacy or business model.

Biohaven (BHVN)

• The speaker clarifies that he is long Biohaven after making several sarcastic remarks.
• He sarcastically implies the company has no investors left, then reveals the opposite is true.
• He states they have "a lot of fans on Wall Street" and that it is "pretty easy for them to raise money."

Takeaways

• The speaker is bullish on Biohaven, believing it has strong institutional support and good access to capital.
• This implies he sees a solid foundation for the company's future growth and funding needs.

Oklo (OKLO)

• The speaker identifies Oklo as a stock to "watch."
• It is described as a "nuclear company" that is developing "fusion reactors."
• He notes a key fundamental detail: the company has "no revenue yet."
• The sentiment is one of cautious, long-term speculation, summarized by the phrase "Hope springs eternal."

Takeaways

• Oklo is a high-risk, high-reward speculative play in the nuclear fusion space.
• It is a pre-revenue company, meaning its value is based entirely on future potential, not current performance.
• This is an idea for a watchlist, not necessarily an immediate investment, for those interested in speculative future technologies.

Cogent Biosciences (COGT)

• The speaker notes that Cogent reported "good data" for gastrointestinal stromal tumors.
• His sentiment is cautiously positive, stating it "seems like a buy still."
• However, he expresses uncertainty about the drug's commercial potential, wondering if it "will be a drug that sells well or not."
• He ultimately decided not to invest, stating he "attempted to sort of ride the momentum, but there's plenty of other trades going on."

Takeaways

• Cogent has positive clinical data, which is a good sign for a biotech company.
• However, there is still uncertainty about its ability to turn that data into a commercially successful product.
• It could be considered a momentum play, but the speaker himself passed on it for other opportunities.